




SHORT REPORT

The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90-90-90 targets

Phillip Keen¹ , Richard T Gray¹ , Barbara Telfer², Rebecca Guy¹, Heather-Marie Schmidt³, Bill Whittaker³, Jo Holden³, Martin Holt⁴ , Anthony Kelleher¹, David Wilson⁵, Denton Callander¹, David A Cooper¹, Garrett Prestage¹, Christine Selvey² and Andrew E Grulich¹ on behalf of the NSW HIV Prevention Partnership Project*

Corresponding author: Phillip Keen, The Kirby Institute, UNSW Sydney, Sydney NSW 2052, Australia. (pkeen@kirby.unsw.edu.au)

*A complete list of the NSW HIV Prevention Partnership Project investigators is given in the Appendix.

Abstract

Introduction: The HIV Strategy in New South Wales (NSW) Australia aims to virtually eliminate HIV transmission by 2020. We estimated the 2016 HIV diagnosis and care cascade for the state of NSW, with a focus on introducing population-based data to improve data quality and assess progress towards the UNAIDS 90-90-90 targets.

Methods: To estimate the number of people living with diagnosed HIV (PLDHIV) we used NSW data from the Australian National HIV Registry, enhanced by surveillance among people recently diagnosed with HIV to improve migration estimates. The number of undiagnosed PLHIV was estimated using back-projection modelling by CD4 count at diagnosis. De-duplicated prescription claims data were obtained from the Australian Pharmaceutical Benefits Scheme (PBS), and were combined with an estimate for those ineligible, to determine the number of PLDHIV on antiretroviral therapy (ART). Data from a clinic network with 87% coverage of PLDHIV in NSW enabled the estimation of the number on ART who had HIV suppression.

Results and discussion: We estimated that 10,110 PLHIV resided in NSW in 2016 (range 8400 to 11,720), among whom 9230 (91.3%) were diagnosed, and 8490 (92.0% of those diagnosed) were receiving ART. Among PLDHIV receiving ART, 8020 (94.5%) had suppressed viral load (<200 HIV-1 RNA copies/mL). Overall, 79.3% of all PLHIV had HIV virological suppression.

Conclusion: NSW has met each of the UNAIDS 90-90-90 targets. The enhanced surveillance methods and data collection systems improved data quality. Measuring and meeting the 90-90-90 targets is feasible and could be achieved in comparable parts of the world.

Keywords: 90-90-90; antiretroviral treatment; continuum of care; HIV; treatment cascade

Received 6 November 2017; Accepted 27 March 2018

Copyright © 2018 The Authors. *Journal of the International AIDS Society* published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 | INTRODUCTION

In 2014, the Joint United Nations Programme on HIV and AIDS (UNAIDS) launched the 90-90-90 targets that by 2020, 90% of people living with HIV (PLHIV) will know their HIV status, 90% of these will receive antiretroviral therapy (ART), and 90% of these will have viral suppression. Overall, this would equate to 73% of all PLHIV being virally suppressed [1].

Several methods have been developed to produce cascade estimates from study populations or by combining population level data [2,3]. A recent systematic review of HIV continua of care (cascade) data reported that only 6 of 53 countries met designated "high quality" criteria, and only Sweden had met all three 90-90-90 targets [4]. Cascades were classified as high quality if they used all the following: [1] national estimates of PLHIV or estimates from nationally representative surveys

and surveillance; [2] a cohort or national programme service database that included everyone diagnosed with HIV; [3] a national cohort or programme service database for those on ART; and [4] individual viral load data for everyone on ART or representative cohort/surveys [4]. An earlier systematic review also recommended the use of population-based data sets to ensure comparability of cascade estimates [5]. In 2017, UNAIDS reported that in 2016 Denmark and a small number of so-called "fast track cities" had also met all three of the 90-90-90 targets. In addition, Botswana, Cambodia, Denmark, Iceland, Singapore, Sweden and the United Kingdom had met the overall goal of 73% or more of people living with HIV having viral suppression [6]. Also in 2017, results from a cluster-randomized trial of a universal HIV testing and treatment intervention in East Africa showed that in communities where the intervention was implemented, the UNAIDS population-level viral suppression target was exceeded [3].

In Australia's most populous state, New South Wales (NSW), the HIV epidemic is concentrated among gay and bisexual men (GBM). Since 1981, 84% of HIV diagnoses have been among men whose reported risk was sex with other men, 3.6% in people who reported injecting drugs and 9.8% among people whose only risk was heterosexual sex [7]. In this report, we estimate the HIV cascade in 2016 in NSW and describe enhanced data collection methods.

2 | METHODS

We estimated the three cascade steps, with an estimated upper and lower bound for each, which we termed the plausible range. We provide a summary of the data sources and calculations with full details available from a technical appendix in the HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report, 2016 [8] and an online repository containing all the code used in the calculations [9].

2.1 | First 90: the proportion of PLHIV who were diagnosed (PLDHIV)

Australia's HIV surveillance system involves mandatory reporting by doctors and laboratories of all HIV diagnoses, including CD4 count at diagnosis, to state and territory health departments who submit these data to a national HIV registry. Where duplicate cases are reported, cases are allocated to a jurisdiction based on postcode of residence at the earliest reported diagnosis [10]. HIV diagnoses among immigrants to Australia are added to the national HIV registry if they have lived in Australia for at least three months and intend to reside in the notifying State/Territory, including among people previously diagnosed overseas [10]. Data were provided on NSW cases reported to 31 December 2016. From the notified number of PLDHIV we subtracted duplicates, estimated deaths, and overseas and interstate migration.

All-cause death rates in PLHIV were based on a linkage study between national HIV and death registers until 2003, and on a large national cohort study of PLHIV since then [11,12]. Two emigration adjustments were applied. First, 6-month follow up of all people notified with HIV in NSW [13] was used to estimate short-term emigration. Second, for longer term emigration, and for interstate movement, we used population data from the Australian Bureau of Statistics (ABS) [14]. We assumed that long term emigration rates and interstate movement for people living with HIV were the same as for the general population. The plausible range for PLDHIV was estimated by multiplying the appropriate lower and upper bounds for the number of deaths and emigrants. The range in deaths was estimated using the 95% confidence interval of the death rate. We assumed the actual emigration rate ranged between zero and double the estimated long-term emigration rate in the overall population.

We then applied the European Centre for Disease Prevention and Control (ECDC) HIV Modelling Tool to estimate the proportion of PLHIV who were undiagnosed, and added this to the estimated number of PLDHIV [15]. The ECDC tool is a multi-state back-calculation model using HIV notification data and estimates for the rate of CD4 decline to fit diagnoses

rates over time, which produces an estimate and range of the undiagnosed population and the percentage undiagnosed. The range in PLHIV was obtained by applying the lower estimate for proportion undiagnosed to the lower limit for PLDHIV and conversely for the upper bound.

2.2 | The second 90: PLDHIV who were receiving ART

We used programme delivery data provided by the Pharmaceutical Benefits Scheme (PBS) on ART prescription claims. The PBS provides a subsidy to cover the cost of ART for people eligible for Medicare in Australia. Only Australian citizens and permanent residents receive this cost subsidy. The PBS collects patient information from pharmacies and produces a de-duplicated dataset. We used data from NSW residents (based on last registered address) between 1 January and 31 December 2016. The PBS does not subsidize ART for temporary Australian residents, whereas NSW surveillance data includes overseas-born people diagnosed with HIV if they have lived in Australia for at least three months prior to diagnosis of HIV, and intend to reside in NSW for at least three months [10,16]. For this reason, we added an estimate of the number of HIV-positive temporary residents in NSW taking ART, based on a survey of clinicians and related cohort study (ATRAS) which estimated there were 450 HIV-positive temporary residents in Australia in 2014 [17]. To estimate the number of HIV-positive temporary residents in NSW taking ART, we first estimated the number of temporary residents living with HIV in NSW by multiplying the national estimate (450) by the cumulative proportion of Australian HIV notifications first diagnosed in NSW (50.2%; giving 226 people). We then assumed 94% of the 180 temporary residents in ATRAS were on treatment (proportion at end of study) and only 63% of the remaining temporary residents were on treatment (matching the baseline proportion on ART from ATRAS). We then calculated the weighted proportion overall (equal to 76%). We then multiplied the estimated population by the proportion on ART. We calculated a range in the number of temporary residents on ART to reflect the uncertainty in the overall population size (400 to 500).

2.3 | The third 90: PLDHIV on ART who were virally suppressed (<200 copies/mL)

We defined virological suppression as less than 200 viral copies per mL. To estimate the proportion of PLDHIV on ART who were virally suppressed, we used programme service delivery data on last viral load test in 2016 from PLDHIV on ART attending a network of NSW clinics in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) project [18]. De-identified patient information from each clinic was collated by ACCESS, and de-duplicated across clinics. Plausible ranges were estimated by calculating the 95% confidence interval for this proportion. During 2015 to 2016, the ACCESS network was enhanced to enable linkage of patients across clinics, and expanded to include additional GPs, hospitals and sexual health clinics. In 2016, across seven general practice clinics, two hospitals and 33 sexual health clinics, the ACCESS network captured 7998 PLDHIV, 86.7% of all PLDHIV in NSW [19]. We estimated the number of

PLDHIV on ART with viral suppression by multiplying this proportion by the estimated number of people receiving ART with a range given by the 95% CI of this proportion. One clinic with over 1000 PLDHIV in care was not included in ACCESS but had a similar proportion of patients who were virally suppressed in 2016 as the overall proportion in ACCESS. (Professor Smith, D.E. (online). E-mail to Phillip Keen (pkeen@kirby.unsw.edu.au) 18 February 2018 (cited 2018 Mar 6)

All calculations were undertaken in R [20]. Reproducible code is available online [9] with cleaned input data and raw result files available on request.

3 | RESULTS

Overall, 79.3% (range 67.2 to 97.4%) of all PLHIV in NSW had suppressed virus (Table 1). The NSW 2016 Cascade data are illustrated graphically in Figure 1.

3.1 | First 90: the proportion of PLHIV who were diagnosed

Data from the Australian National HIV Registry showed that 19,099 people had been diagnosed in NSW to 31 December 2016. The ABS [14] estimated that 0.44% of NSW residents emigrated overseas in 2016 [17,21]. In follow-up of people diagnosed with HIV, 50 (4.8%) of 1043 NSW residents newly diagnosed with HIV from 2013 to 2015 had emigrated in the first six months following diagnosis. This short-term emigration was substantially higher in people born overseas (47 of 486 diagnoses, 9.7%) than in people born in Australia (3 of 557, 0.5%) [13].

Table 1. NSW HIV diagnosis and care cascade estimates to 31 December 2016. Numbers rounded to the nearest 10

Cascade indicator	2016	Percentage of previous cascade indicator (%) ^a	Percentage of all PLHIV (%)
All PLHIV ^b	10,110 (8400 to 11,720)	-	100
PLDHIV ^c	9230 (8470 to 10,490)	91.3	91.3
Number PLDHIV on ART	8490 (8470 to 8520)	92.0	83.9
Number PLDHIV on ART with suppressed virus ^d	8020 (7870 to 8180)	94.5	79.3

^aPercentages of the previous indicator shown correspond to the UNAIDS 90-90-90 targets.

^bAll PLHIV includes the estimated number of undiagnosed and diagnosed people living with HIV.

^cPLDHIV is the estimated number of people living with HIV who were diagnosed and residing in NSW.

^dThe estimated number of people living with HIV who were on ART and had viral suppression (<200 HIV-1 RNA copies/mL).

Overall, we estimated that by end 2016, 10,110 (range 8400 to 11,720) people were living with HIV in NSW, of whom 9230 (range 8470 to 10,490) or 91.3% were diagnosed. The percentage undiagnosed was 8.7% overall and was lower in men reporting male-to-male sex exposure risk (8.4%) than in others (11.5%).

3.2 | The second 90: PLDHIV who were receiving ART

There were 8315 NSW residents who received subsidized ART through the PBS in 2016. Among Australian temporary residents living with HIV we assumed that the 2014 data were unchanged in 2016 and that they applied to NSW [17,21] and estimated that there were 172 (range 151 to 201) temporary residents on ART in NSW in 2016 [8].

Overall, we estimated that 8490 (range 8470 to 8520) or 92.0% of PLDHIV were receiving ART.

3.3 | The third 90: PLDHIV on ART who were virally suppressed (<200 copies/mL)

Among 7598 PLDHIV receiving ART in the ACCESS clinic network, representing 89.5% of PLDHIV on ART in NSW, 94.5% were virally suppressed.

Based on this we estimated 8020 (95%CI: 7870 to 8180) of PLDHIV had a suppressed viral load (<200 copies/mL).

4 | DISCUSSION

In 2016, the UNAIDS 90-90-90 targets were exceeded in NSW. Of all PLHIV, 91.3% were diagnosed, 92.0% of those were on ART, and 94.5% of those had suppressed viral load. The percentage of all PLHIV in NSW who had suppressed viral load, of 79.3%, is to the best of our knowledge the highest thus far reported for a jurisdiction in the peer-reviewed literature. Enhanced systems were developed to utilize population-level data on ART use, viral load and migration to improve the quality of the NSW cascade.

There have been substantial changes to HIV testing and treatment in NSW in recent years. HIV testing at publicly funded sexual health clinics increased 85% from 30,091 tests in 2014 to 55,761 tests in 2016 [7,22]. The percentage of PLDHIV on ART in NSW has also increased rapidly over recent years. In HIV-positive GBM, self-reported use of ART increased from 66% in 2006 to 80.6% in 2011 and to 92% in 2016 [23-25]. In comparison, the percentage of PLDHIV on ART with suppressed viral load has increased less substantially over time. In 2006, in a large observational cohort of NSW PLDHIV it was already high, at 87% [26].

There are a number of factors which may have contributed to the achievement of the 90-90-90 targets in NSW. In NSW, the virtual elimination of HIV by 2020 has been the explicit goal in two consecutive HIV strategies, commencing in 2012 [27,28]. Since then, a range of new HIV prevention initiatives aimed at increasing HIV testing and treatment have been implemented. For HIV testing there has been widespread promotion; the introduction of rapid HIV testing at public, private and peer-led community clinics; and the introduction of streamlined testing services for high-risk populations. In terms




Figure 1. NSW HIV diagnosis and care cascade, 2016, showing the estimated proportion of people living with HIV (PLHIV) at each cascade indicator. Horizontal dotted lines indicate each of the 2014 Joint United Nations Programme on HIV and AIDS (UNAIDS) 90-90-90 targets. Columns indicate the number of PLHIV at each cascade step. Numbers within the columns indicate the proportion of all PLHIV at each cascade step. Range bars in columns indicate the estimated plausible range for each cascade step.

of treatment, Australian clinical guidelines have changed to recommend treatment soon after HIV diagnosis, and there has been a sustained drive to implement these guidelines with aggressive treatment uptake targets in the NSW HIV Strategies [27,28]. There has been education to providers regarding treatment guidelines, and promotion of the benefits of early treatment to PLHIV. Access to HIV treatment has been made easier through dispensing at community pharmacies and co-payments associated with the receipt of ART have been removed in NSW [27-29].

In parallel there have been extensive efforts to enhance the quality of data systems. First, the initiation of enhanced surveillance at six months following diagnosis identified that the emigration rate among PLDHIV after diagnosis was higher than previously estimated and we believe this provides a more accurate population estimate of PLHIV [13]. These findings are consistent with results of a study in King County, Washington where follow-up efforts resulted in the identification of PLHIV who had emigrated, resulting in more accurate population estimates [30,31]. Second, rather than relying on patient cohorts or surveys we established systems to provide de-duplicated programme service delivery data on PBS-subsidized ART prescription claims, allowing us to report population-level data on ART. We established a system that extracts de-identified programme service delivery data on viral load results and de-duplicates across 42 clinics in a network that was expanded to ensure over 85% coverage of PLDHIV in NSW [7]. NSW has been reporting quarterly on the number of people newly diagnosed with HIV who initiate treatment within three and six months of diagnosis [7].

There are a few potential considerations in our data. First, directly collected information on emigration from NSW and Australia were only available for HIV diagnoses from 2013, and only for the first six months after diagnosis and we assumed that longer term migration rates for PLDHIV were

the same as general population rates. Second, we assumed that the proportion of PLDHIV who are ineligible for subsidized ART had not changed since 2014, and that the NSW proportion was the same as the Australia-wide estimate [32]. Third, it is possible that viral load suppression rates may be different among a small proportion of PLHIV who are not attending the ACCESS clinics or the additional large clinic we contacted. However, due to the high proportion of PLDHIV included in the ACCESS network and the additional clinic, any lower rates of viral suppression among PLDHIV attending other clinics would have little influence on estimates.

5 | CONCLUSIONS

Based on our estimates, we believe that NSW has met each of the UNAIDS 90-90-90 targets and achieved an overall rate of 79.3% of PLHIV with virological suppression. This to the best of our knowledge is the highest rate reported in the peer-reviewed literature. The enhanced data collection systems introduced in NSW introduced population level data on ART use and viral load that now meet criteria for high-quality cascade data [4] and could be utilized in other settings. Efforts are continuing to surpass these goals with the current NSW HIV Strategy 2016 to 2020 setting a target to have 95% of all people diagnosed with HIV on ART [28].

AUTHORS' AFFILIATIONS

¹The Kirby Institute, UNSW Sydney, Sydney, Australia; ²Health Protection NSW, Sydney, Australia; ³NSW Ministry of Health, Sydney, Australia; ⁴Centre for Social Research in Health, UNSW Sydney, Sydney, Australia; ⁵The Burnet Institute, Melbourne, Australia

COMPETING INTERESTS

The authors have no conflicts of interest to disclose.

AUTHORS' CONTRIBUTIONS

RTG, RG, PK and AG conceptualized the study and data analysis plan. BT, CS, DC, RG, H-MS and JH extracted and collected data. RTG, DC, RG and BT performed the data analysis. PK, AG, and RTG drafted the manuscript. RG, H-MS, BW, AK, MH, DAC, CS and DPW reviewed and commented on initial and final drafts of the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGEMENTS

The authors wish to acknowledge the contribution of NSW Health Enhanced Surveillance Project, which provided data on residency status at six months following HIV diagnosis among people diagnosed with HIV in NSW since 2013. In addition, Jason Asselin, Clarissa Moreira and Carol El-Hayek of the Burnet Institute, and Hamish McManus of the Kirby Institute assisted with preparation of data from the ACCESS project.

FUNDING

The Kirby Institute and the Centre for Social Research in Health are funded by the Australian Government Department of Health and Ageing. The Kirby Institute is affiliated with the Faculty of Medicine, UNSW, Sydney. This study was funded by a NHMRC Partnership Grant (grant # 1092852), the NSW Ministry of Health, and UNSW, Sydney. The ACCESS study is funded by the Australian Department of Health and Ageing. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned previously.

APPENDIX

The investigators on the NSW HIV Prevention Partnership Project are Professor Andrew Grulich, Dr Christine Selvey, Professor Rebecca Guy, Associate Professor Garrett Prestage, Associate Professor Iryna Zablotska, Ms Jo Holden, Mr Tim Duck, Mr Craig Cooper, Ms Karen Price, Professor Martin Holt, Professor John de Wit, Professor John Kaldor, Professor Anthony Kelleher, and Professor David Wilson. The project steering committee includes these investigators and Mr Bill Whittaker, Mr Phillip Keen, Dr Denton Callander, Dr Heather-Marie Schmidt and Ms Barbara Telfer. The late Mr Alan Brotherton, the late Adjunct Associate Professor Levinia Crooks, and the late Professor David A Cooper were also investigators on the project grant.

REFERENCES

1. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. **2014**; JC2684. Geneva: UNAIDS; 2014 [cited 2017 May 05] Available from: <http://www.unaids.org/en/resources/documents/2017/90-90-90>
2. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. *Lancet HIV*. **2016**;3(5):e221–30.
3. Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, et al. Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa. *JAMA*. **2017**;317(21):2196–206.
4. Granich R, Gupta S, Hall I, Aberle-Grasse J, Hader S, Mermin J. Status and methodology of publicly available national HIV care continua and 90-90-90 targets: a systematic review. *PLoS Med*. **2017**;14(4):e1002253.
5. Medland NA, McMahon JH, Chow EP, Elliott JH, Hoy JF, Fairley CK. The HIV care cascade: a systematic review of data sources, methodology and comparability. *J Int AIDS Soc*. **2015**;18(1):20634.
6. Joint United Nations Programme on HIV/AIDS (UNAIDS). Ending AIDS: Progress Towards the 90-90-90 Targets. **2017** [cited 2017 Aug 28] Available from: http://www.unaids.org/en/resources/documents/2017/20170720_Global_AIDS_update_2017

7. NSW Ministry of Health. NSW HIV Strategy 2016-2020 Quarter 4 & Annual 2016 Data Report. Sydney; **2017** [cited 2017 May 31] Available from: <http://www.health.nsw.gov.au/endinghiv/Documents/q4-2016-annual-hiv-data-report.pdf>
8. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2016. The Kirby Institute. Sydney NSW 2052; **2016** [cited 2017 May 31] Available from: <https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-stis-2016>
9. Gray RT. leftygray/Cascade_calculations: Version used for the 2017 Annual Surveillance Report. Zenodo. **2017** [cited 2017 Sep 28] Available from: <https://doi.org/10.5281/zenodo.998280>. Also available at: https://github.com/leftygray/Cascade_calculations
10. The Kirby Institute. Surveillance, Evaluation and Research Program Standard Operating Procedures: National HIV/AIDS Case Reporting. Sydney; **2017** [cited 2017 July 3] Available from: https://kirby.unsw.edu.au/sites/default/files/kirby/report/SERP_Standard-Operating-Procedures-National-HIV-AIDS-Case-Reporting_Mar%202017.pdf
11. Nakhaee F, Black D, Wand H, McDonald A, Law M. Changes in mortality following HIV and AIDS and estimation of the number of people living with diagnosed HIV/AIDS in Australia, 1981-2003. *Sex Health*. **2009**;6(2):129–34.
12. The Kirby Institute. Australian HIV Observational Database Annual Report. Sydney; **2014** [cited 2017 June 1] Available from: https://kirby.unsw.edu.au/sites/default/files/AHOD_Report-2014.pdf
13. NSW Ministry of Health. NSW HIV Strategy 2016-2020 Quarter 2 2016 Data Report. Sydney; **2016** [cited 2017 June 1] Available from: <http://www.health.nsw.gov.au/endinghiv/Documents/q2-2016-nsw-hiv-data-report.pdf>
14. Australian Bureau of Statistics. 3101.0 - Australian Demographic Statistics, Dec 2016: Australian Bureau of Statistics; 2017 [cited 2017 July 14] Available from: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0>
15. van Sighem A, Nakagawa F, De Angelis D, Quinten C, Bezemer D, de Coul EO, et al. Estimating HIV incidence, time to diagnosis, and the undiagnosed HIV epidemic using routine surveillance data. *Epidemiology*. **2015**;26(5):653–60.
16. NSW Ministry of Health. Notification of HIV Infection or Death of a Person with HIV Infection. **2016** [cited 2017 Sep 06] Available from: <http://www.health.nsw.gov.au/Infectious/Forms/hiv-notification-form.pdf>
17. Petoumenos K, Watson J, Whittaker B, Hoy J, Smith D, Bastian L, et al. Subsidized optimal ART for HIV-positive temporary residents of Australia improves virological outcomes: results from the Australian HIV Observational Database Temporary Residents Access Study. *J Int AIDS Soc*. **2015**;18:19392.
18. Guy RJ, Kong F, Goller J, Franklin N, Bergeri I, Dimech W, et al. A new national Chlamydia Sentinel Surveillance System in Australia: evaluation of the first stage of implementation. *Commun Dis Intell Q Rep*. **2010**;34(3):319–28.
19. Callander D, Stooze M, Carr A, Hoy JF, Petoumenos K, Hellard M, et al. A longitudinal cohort study of HIV 'treatment as prevention' in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol. *BMC Infect Dis*. **2016**;16(1):752.
20. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; **2016**.
21. Gray RT, Watson J, Cogle AJ, Smith DE, Hoy JF, Bastian LA, et al. Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive. *Sexual Health*. **2018**;15(1):13–9.
22. NSW Ministry of Health. NSW HIV Strategy 2012-2015 Annual 2014 Data report. Sydney; **2015** [cited 2017 July 03] Available from: <http://www.health.nsw.gov.au/endinghiv/Documents/annual-2014-hiv-data-report.pdf>
23. Hull P, Mao L, Kolstee J, Duck T, Feeney L, et al. Gay Community Periodic Survey: Sydney 2016. Centre for Social Research in Health, UNSW Australia; **2016** [cited 2017 June 16] Available from: https://csr.h.arts.unsw.edu.au/media/CSRHFile/Sydney_2016_GCPS_report.pdf
24. Zablotska I, Prestage G, Frankland A, Chong S, Sutherland R, Corrigan N, et al. Gay Community Periodic Survey: Sydney, February 2007. Sydney: National Centre in HIV Social Research, The University of New South Wales; **2007** [cited 2017 July 17] Available from: <https://doi.org/10.4225/53/5750e85c36a7a>
25. Hull P, Mao L, Kolstee J, Duck T, Feeney L, Prestage G, et al. Gay Community Periodic Survey: Sydney 2013. Sydney: National Centre in HIV Social Research, University of New South Wales; **2013** [cited 2017 Sep 15] Available from: https://csr.h.arts.unsw.edu.au/media/CSRHFile/GCPS_Sydney_2013_Report.pdf
26. Falster K, Gelgor L, Shaik A, Zablotska I, Prestage G, Grierson J, et al. Trends in antiretroviral treatment use and treatment response in three Australian states in the first decade of combination antiretroviral treatment. *Sex Health*. **2008**;5(2):141–54.
27. NSW Centre for Population Health. NSW HIV Strategy 2012-2015: A New Era. Sydney: NSW Ministry of Health; **2012** [cited 2017 May 31] Available

from: <http://www.health.nsw.gov.au/publications/Publications/nsw-hiv-strategy-2012-15.pdf>

28. NSW Ministry of Health. NSW HIV Strategy 2016-2020. Sydney; 2015 [cited 2017 April 10] Available from: <http://www.health.nsw.gov.au/endinghiv/Publications/nsw-hiv-strategy-2016-2020.PDF>

29. NSW Health. Changes to Co-Payments for Section 100 Highly Specialised Drugs and Section 100 Injectable and Infusible Chemotherapy Medicines in NSW. 2017 [cited 2017 June 01] Available from: <http://www.health.nsw.gov.au/pharmaceutical/Pages/s100-copayments.aspx>

30. Buskin SE, Kent JB, Dombrowski JC, Golden MR. Migration distorts surveillance estimates of engagement in care: results of public health investigations of persons who appear to be out of HIV care. *Sex Transm Dis.* 2014;41(1):35–40.

31. Dombrowski JC, Buskin SE, Bennett A, Thiede H, Golden MR. Use of multiple data sources and individual case investigation to refine surveillance-based estimates of the HIV care continuum. *J Acquir Immune Defic Syndr.* 2014;67(3):323–30.

32. Gray RT, Watson JCA, Smith DE, Hoy JF, Bastian LA, Finlayson R, et al. Funding ART for HIV-positive temporary residents in Australia prevents transmission and is inexpensive. *Sex Health.* 2017;15:13–9.